MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation

Cardiovascular Research

Volumn 95, Issue 4, 2012, Pages 517-526

  Wang, Yung Song ^a   Wang, Hay Yan J ^b   Liao, Yi Chu ^a,c,d   Tsai, Pei Chien ^a   Chen, Ku Chung ^a   Cheng, Hsin Yun ^a   Lin, Ruey Tay ^a,e   Juo, Suh Hang Hank ^a,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Atherosclerosis; Balloon injured carotid artery; Human aorta smooth muscle cell; MicroRNA 195; Neointimal formation

Indexed keywords

ADENOVIRUS VECTOR; CARDIOVASCULAR AGENT; CYCLIN D1; FIBROBLAST GROWTH FACTOR 1; GENE THERAPY AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA 195; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN CDC42; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROARRAY ANALYSIS; NEOINTIMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CDC42 GTP-BINDING PROTEIN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; CYCLIN D1; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPROTEINS, LDL; MALE; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSFECTION;

EID: 84865253634     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs223     Document Type: Article

References (51)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-739.
3. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-385.
4. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Em-miR155 transgenic mice. Proc Natl Acad Sci USA 2006;103:7024-7029.
5. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-355.
6. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006;94:776-780.
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
8. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
9. Suárez Y, Fernández-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008;105:14082-14087.
10. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108:3068-3071.
11. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009;104:476-487.
12. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neoin-timal lesion formation. Circ Res 2007;100:1579-1588.
13. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009;105:158-166.
14. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. Faseb J 2011;25:1718-1728.
15. Han M, Toli J, Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol 2011;26:181-189.
16. Chen KC, Juo SH. MicroRNAs in atherosclerosis. Kaohsiung J Med Sci 2012; doi: 10.1016/j.kjms.2012.04.001. Published online ahead of print 6 August 2012.
17. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011;17:1722-1730.
18. Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-b-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol 2011;226:2535-2542.
19. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-121.
20. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol 2004;2:e363.
21. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
22. Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 2011;13:R24.
23. Chotani MA, Touhalisky K, Chiu IM. The small GTPases Ras, Rac, and Cdc42 tran-scriptionally regulate expression of human fibroblast growth factor 1. J Biol Chem 2000;275:30432-30438.
24. Bauerfeld CP, Hershenson MB, Page K. Cdc42, but not Rho A, regulates cyclin D1 expression in bovine tracheal myocytes. Am J Physiol Lung Cell Mol Physiol 2001;280: L974-982.
25. Ammit AJ, Panettieri RA Jr. Invited review: the circle of life: cell cycle regulation in airway smooth muscle. J Appl Physiol 2001;91:1431-1437.
26. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991;11:1166-1174.
27. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990;85:731-738.
28. Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL et al. Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 1994;75:1-7.
29. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA et al. Liposomal delivery of purified inhibitory-kBa inhibits tumor necrosis factor-a-induced human vascular smooth muscle proliferation. Circ Res 1999;84:867-875.
30. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991;260:H1713-1717.
31. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10:2327-2334.
32. Henness S, van Thoor E, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A acts via p38 MAPK to increase stability of TNF-a-induced IL-8 mRNA in human ASM. Am J Physiol Lung Cell Mol Physiol 2006;290:L1283-1290.
33. Jung YD, Fan F, McConkey DJ, Jean ME, Liu W, Reinmuth N et al. Role of P38 MAPK, AP-1, and NF-kB in interleukin-1b-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 2002;18:206-213.
34. Ryoo SW, Kim DU, Won M, Chung KS, Jang YJ, Oh GT et al. Native LDL induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. Cardiovasc Res 2004;62:185-193.
35. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 2005;96:172-179.
36. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262.
37. 2+/calmodulin-dependent protein kinase II in the mitogen-activated protein kinase signaling cascade of cultured rat aortic vascular smooth muscle cells. Circ Res 1997;81:575-584.
38. Liu L, Chen L, Xu Y, Li R, Du X. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 2010; 400:236-240.
39. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011;92:75-84.
40. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010;15:673-682.
41. Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-b-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol 2010;226:2535-2542.
42. Schmitz U, Thömmes K, Beier I, Vetter H. Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 2002;291:687-691.
43. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 1998;282:1717-1721.
44. Daniels RH, Bokoch GM. p21-activated protein kinase: a crucial component of morphological signaling?. Trends Biochem Sci 1999;24:350-355.
45. Zettler ME, Prociuk MA, Austria JA, Massaeli H, Zhong G, Pierce GN. OxLDL stimulates cell proliferation through a general induction of cell cycle proteins. Am J Physiol Heart Circ Physiol 2003;284:H644-653.
46. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001;21:1152-1158.
47. Karpurapu M, Wang D, Van Quyen D, Kim TK, Kundumani-Sridharan V, Pulusani S et al. Cyclin D1 is a bona fide target gene of NFATc1 and is sufficient in the mediation of injury-induced vascular wall remodeling. J Biol Chem 2010;285:3510-3523.
48. Chiang JK, Sung ML, Yu HR, Chang HI, Kuo HC, Tsai TC et al. Homocysteine induces smooth muscle cell proliferation through differential regulation of cyclins A and D1 expression. J Cell Physiol 2011;226:1017-1026.
49. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
50. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997;25:320-325.
51. Daley SJ, Gotlieb AI. Fibroblast growth factor receptor-1 expression is associated with neointimal formation in vitro. Am J Pathol 1996;148:1193-1202.